Influence of Acarbose on Plasma Glucose Fluctuations in Insulin-Treated Patients with Type 2 Diabetes: A Pilot Study

International Journal of Endocrinology

Volumn 2015, Issue , 2015, Pages

  Li, Feng Fei ^a   Xu, Xiao Hua ^a   Fu, Li Yuan ^b   Su, Xiao Fei ^a   Wu, Jin Dan ^a   Lu, Chun Feng ^a   Ye, Lei ^c   Ma, Jian Hua ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

^c DEPARTMENT OF CARDIOLOGY   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; RECOMBINANT HUMAN INSULIN;

ADD ON THERAPY; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BIOSENSOR; BLOOD GLUCOSE MONITORING; COMBINATION CHEMOTHERAPY; CONTINUOUS GLUCOSE MONITORING SYSTEM; CONTROLLED STUDY; DRUG DOSE TITRATION; DRUG EFFICACY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION;

EID: 84948695792     PISSN: 16878337     EISSN: 16878345     Source Type: Journal    
DOI: 10.1155/2015/903524     Document Type: Article

References (29)

1. H. Bischoff, "The mechanism of α-glucosidase inhibition in the management of diabetes, " Clinical and Investigative Medicine, vol. 18, no. 4, pp. 303-311, 1995.
2. F. A. van de Laar, P. L. Lucassen, R. P. Akkermans, E. H. Van De Lisdonk, G. E. Rutten, and C. van Weel, "α-glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis, " Diabetes Care, vol. 28, no. 1, pp. 154-163, 2005.
3. G. S. Meneilly, E. A. Ryan, J. Radziuk et al., "Effect of acarbose on insulin sensitivity in elderly patients with diabetes, " Diabetes Care, vol. 23, no. 8, pp. 1162-1167, 2000.
4. A. Calle-Pascual, J. Garcia-Honduvilla, P. J. Martin-Alvarez, J. R. Calle, and J. P. Maranes, "Influence of 16-week monotherapy with acarbose on cardiovascular risk factors in obese subjects with non-insulin-dependent diabetes mellitus: a controlled, double-blind comparison study with placebo, " Diabetes and Metabolism, vol. 22, no. 3, pp. 201-202, 1996.
5. T. Nakagami, "Hyperglycaemia and mortality from all causes and from cardiovascular disease in five populations of Asian origin, " Diabetologia, vol. 47, no. 3, pp. 385-394, 2004.
6. L. Monnier, E. Mas, C. Ginet et al., "Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes, " The Journal of the AmericanMedical Association, vol. 295, no. 14, pp. 1681-1687, 2006.
7. A. Ceriello, L. Quagliaro, B. Catone et al., "Role of hyperglycemia in nitrotyrosine postprandial generation, " Diabetes Care, vol. 25, no. 8, pp. 1439-1443, 2002.
8. J. Zhou, H. Li, X. Zhang et al., "Nateglinide and acarbose are comparably effective reducers of postprandial glycemic excursions in chinese antihyperglycemic agent-naive subjects with type 2 diabetes, " Diabetes Technology andTherapeutics, vol. 15, no. 6, pp. 481-488, 2013.
9. Y. Kusunoki, T. Katsuno, M. Myojin et al., "Effect of additional administration of acarbose on blood glucose fluctuations and postprandial hyperglycemia in patients with type 2 diabetes mellitus under treatment with alogliptin, " Endocrine Journal, vol. 60, no. 4, pp. 431-439, 2013.
10. D. E. Kelley, P. Bidot, Z. Freedman et al., "Efficacy and safety of acarbose in insulin-treated patients with type 2 diabetes, " Diabetes Care, vol. 21, no. 12, pp. 2056-2061, 1998.
11. O. Schnell, G. Mertes, and E. Standl, "Acarbose and metabolic control in patients with type 2 diabetes with newly initiated insulin therapy, " Diabetes, Obesity and Metabolism, vol. 9, no. 6, pp. 853-858, 2007.
12. S. Del Prato, "In search of normoglycaemia in diabetes: controlling postprandial glucose, " International Journal of Obesity, vol. 26, supplement 3, pp. S9-S17, 2002.
13. R. Ziegler, C. Tubili, A. Chico et al., "Proact study: new features of insulin pumps improve diabetes management and glycemic control in patients after transition of continuous subcutaneous insulin infusion systems, " Diabetes Technology andTherapeutics, vol. 15, no. 9, pp. 738-743, 2013.
14. J. Weng, Y. Li, W. Xu et al., "Effect of intensive insulin therapy on β-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallelgroup trial, " The Lancet, vol. 371, no. 9626, pp. 1753-1760, 2008.
15. J. Zhou, H. Li, X. Ran et al., "Reference values for continuous glucose monitoring in Chinese subjects, " Diabetes Care, vol. 32, no. 7, pp. 1188-1193, 2009.
16. F. J. Service, G. D. Molnar, J. W. Rosevear, E. Ackerman, L. C. Gatewood, and W. F. Taylor, "Mean amplitude of glycemic excursions, a measure of diabetic instability, " Diabetes, vol. 19, no. 9, pp. 644-655, 1970.
17. J.-L. Chiasson, R. G. Josse, J. A. Hunt et al., "The efficacy of acarbose in the treatment of patients with non-insulindependent diabetes mellitus: a multicenter controlled clinical trial, " Annals of Internal Medicine, vol. 121, no. 12, pp. 928-935, 1994.
18. R. R. Holman, C. A. Cull, and R. C. Turner, "A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (U. K. Prospective Diabetes Study 44), " Diabetes Care, vol. 22, no. 6, pp. 960-964, 1999.
19. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group, "Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy, " The New England Journal of Medicine, vol. 342, no. 6, pp. 381-389, 2000.
20. UK Prospective Diabetes Study (UKPDS) Group, "Intensive blood-glucose controlwith sulphonylureas or insulin compared with conventional treatment and risk of complications in patientswith type 2 diabetes (UKPDS 33), " The Lancet, vol. 352, no. 9131, pp. 837-853, 1998.
21. D. M. Nathan, J. Kuenen, R. Borg, H. Zheng, D. Schoenfeld, and R. J. Heine, "Translating the A1C assay into estimated average glucose values, " Diabetes Care, vol. 31, no. 8, pp. 1473-1478, 2008.
22. Y.-Q. Bao, J. Zhou, M. Zhou et al., "Glipizide controlled-release tablets, with or without acarbose, improve glycaemic variability in newly diagnosed type 2 diabetes, " Clinical and Experimental Pharmacology and Physiology, vol. 37, no. 5-6, pp. 564-568, 2010.
23. M. K. Kim, J. H. Suk, M. J. Kwon et al., "Nateglinide and acarbose for postprandial glucose control after optimizing fasting glucose with insulin glargine in patients with type 2 diabetes, " Diabetes Research and Clinical Practice, vol. 92, no. 3, pp. 322-328, 2011.
24. DECODE Study Group the European Diabetes Epidemiology Group, "Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria, " Archives of Internal Medicine, vol. 161, no. 3, pp. 397-405, 2001.
25. M. Brownlee, "The pathobiology of diabetic complications: a unifying mechanism, " Diabetes, vol. 54, no. 6, pp. 1615-1625, 2005.
26. J.-L. Chiasson, R. G. Josse, R. Gomis, M. Hanefeld, A. Karasik, and M. Laakso, "Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial, " The Journal of the American Medical Association, vol. 290, no. 4, pp. 486-494, 2003.
27. T. Kato, T. Inoue, and K. Node, "Postprandial endothelial dysfunction in subjects with new-onset type 2 diabetes: an acarbose and nateglinide comparative study, " Cardiovascular Diabetology, vol. 9, article 12, 2010.
28. G. Derosa, P. Maffioli, I. Ferrari et al., "Acarbose actions on insulin resistance and inflammatory parameters during an oral fat load, " European Journal of Pharmacology, vol. 651, no. 1-3, pp. 240-250, 2011.
29. D. LeRoith, V. Fonseca, and A. Vinik, "Metabolic memory in diabetes-focus on insulin, " Diabetes/Metabolism Research and Reviews, vol. 21, no. 2, pp. 85-90, 2005.